Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
EDQM
0
USP
0
JP
0
Others
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
FDF
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Ag10 Hydrochloride
2. Ag-10 Hydrochloride
3. Alxn2060 Hydrochloride
4. Acoramidis (hydrochloride)
5. Alxn-2060 Hydrochloride
6. Vy9c88c2nv
7. Acoramidis Hydrochloride [usan]
8. 2242751-53-5
9. Benzoic Acid, 3-(3-(3,5-dimethyl-1h-pyrazol-4-yl)propoxy)-4-fluoro-, Hydrochloride (1:1)
10. Unii-vy9c88c2nv
11. Chembl4650226
12. Schembl20475239
13. Acoramidis Hydrochloride [jan]
14. Hy-109165a
15. Cs-0143619
16. 3-(3-(3-5-dimethyl-1h-pyrazol-4-yl)propoxy)-4-fluorobenzoic Acid Hydrochloride
Molecular Weight | 328.76 g/mol |
---|---|
Molecular Formula | C15H18ClFN2O3 |
Hydrogen Bond Donor Count | 3 |
Hydrogen Bond Acceptor Count | 5 |
Rotatable Bond Count | 6 |
Exact Mass | 328.0989983 g/mol |
Monoisotopic Mass | 328.0989983 g/mol |
Topological Polar Surface Area | 75.2 Ų |
Heavy Atom Count | 22 |
Formal Charge | 0 |
Complexity | 356 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.
NDC Package Code : 59116-5910
Start Marketing Date : 2021-12-30
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 59116-5911
Start Marketing Date : 2021-12-30
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 59116-5911
Start Marketing Date : 2021-12-30
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 59116-5910
Start Marketing Date : 2021-12-30
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.
About the Company : Established in 2004, Metrochem API is one of the fastest-growing APIs, pellets & intermediates manufacturers. It has 6 dedicated manufacturing facilities for its 3 core product gro...
About the Company : HRV Global is a leading global manufacturer, seller & exporter of a wide range of APIs, advanced intermediates, pellets, food grade chemicals, food additives & food ingredients. It...
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Details:
Beyonttra (acoramidis hydrochloride) is an orally administered near-complete stabilizer of TTR for the treatment of transthyretin amyloidosis in adult patients with cardiomyopathy.
Lead Product(s): Acoramidis Hydrochloride
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Beyonttra
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: HealthCare Royalty
Deal Size: $300.0 million Upfront Cash: $300.0 million
Deal Type: Agreement June 30, 2025
Lead Product(s) : Acoramidis Hydrochloride
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : HealthCare Royalty
Deal Size : $300.0 million
Deal Type : Agreement
BridgeBio Raises $300 Million Through Partial Capped Monetization
Details : Beyonttra (acoramidis hydrochloride) is an orally administered near-complete stabilizer of TTR for the treatment of transthyretin amyloidosis in adult patients with cardiomyopathy.
Product Name : Beyonttra
Product Type : Other Small Molecule
Upfront Cash : $300.0 million
June 30, 2025
Details:
Attruby (acoramidis) is a transthyretin stabilizer being investigated for the treatment of younger patients with cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM).
Lead Product(s): Acoramidis Hydrochloride
Therapeutic Area: Genetic Disease Brand Name: Attruby
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 13, 2025
Lead Product(s) : Acoramidis Hydrochloride
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
First Participant Dosed with Acoramidis in ATTR ACT-EARLY Prevention Study
Details : Attruby (acoramidis) is a transthyretin stabilizer being investigated for the treatment of younger patients with cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM).
Product Name : Attruby
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 13, 2025
Details:
Beyonttra is an orally administered stabilizer of transthyretin (TTR) indicated for the treatment of wild-type or variant transthyretin amyloidosis in adult patients with cardiomyopathy.
Lead Product(s): Acoramidis Hydrochloride
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Beyonttra
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 28, 2025
Lead Product(s) : Acoramidis Hydrochloride
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
BEYONTTRA Approved in UK for ATTR-CM As A Near-Complete TTR Stabilizer
Details : Beyonttra is an orally administered stabilizer of transthyretin (TTR) indicated for the treatment of wild-type or variant transthyretin amyloidosis in adult patients with cardiomyopathy.
Product Name : Beyonttra
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 28, 2025
Details:
Beyonttra (acoramidis) is a next-generation, orally-administered, highly potent, small molecule stabiliser of transthyretin. It is approved for the treatment of Transthyretin Amyloid Cardiomyopathy.
Lead Product(s): Acoramidis Hydrochloride
Therapeutic Area: Genetic Disease Brand Name: Beyonttra
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 27, 2025
Lead Product(s) : Acoramidis Hydrochloride
Therapeutic Area : Genetic Disease
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Beyonttra (Acoramidis) Approved in Japan as First Near-Complete TTR Stabilizer
Details : Beyonttra (acoramidis) is a next-generation, orally-administered, highly potent, small molecule stabiliser of transthyretin. It is approved for the treatment of Transthyretin Amyloid Cardiomyopathy.
Product Name : Beyonttra
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 27, 2025
Regulatory Info : RX
Registration Country : USA
Brand Name : ATTRUBY
Dosage Form : TABLET;ORAL
Dosage Strength : EQ 356MG BASE
Packaging :
Approval Date : 2024-11-22
Application Number : 216540
Regulatory Info : RX
Registration Country : USA
RLD : Yes
TE Code :
Brand Name : ATTRUBY
Dosage Form : TABLET;ORAL
Dosage Strength : EQ 356MG BASE
Approval Date : 2024-11-22
Application Number : 216540
RX/OTC/DISCN : RX
RLD : Yes
TE Code :
https://www.pharmacompass.com/radio-compass-blog/fda-okays-50-new-drugs-in-2024-bms-cobenfy-lilly-s-kisunla-lead-pack-of-breakthrough-therapies
20 May 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/05/20/3084731/0/en/Acoramidis-Reduced-Incidence-of-Atrial-Fibrillation-Events-in-Patients-with-ATTR-CM.html
19 May 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/05/19/3084268/0/en/Early-and-Sustained-Increase-in-Serum-TTR-Levels-by-Acoramidis-Independently-Predicted-Improved-Survival-in-the-ATTRibute-CM-Study.html
13 May 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/05/13/3079989/0/en/First-Participant-Dosed-with-Acoramidis-in-ACT-EARLY-the-First-Ever-ATTR-Primary-Prevention-Study.html
28 Apr 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/04/28/3068975/0/en/BEYONTTRA-acoramidis-the-First-Near-complete-TTR-Stabilizer-90-Approved-by-the-UK-Medicines-and-Healthcare-Products-Regulatory-Agency-to-Treat-ATTR-CM.html
27 Aug 2023
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2023/08/27/2732246/0/en/BridgeBio-presents-detailed-positive-results-from-Phase-3-ATTRibute-CM-study-of-acoramidis-for-patients-with-transthyretin-amyloid-cardiomyopathy-ATTR-CM-at-European-Society-of-Car.html
17 Jul 2023
// Max Bayer FIERCE BIOTECH
https://www.fiercebiotech.com/biotech/bridgebio-heart-disease-drug-vindicated-phase-3-victory-plots-fda-submission-23
Market Place
Reply
26 Feb 2025
Patents & EXCLUSIVITIES
ABOUT THIS PAGE
12
PharmaCompass offers a list of Acoramidis Hydrochloride API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Acoramidis Hydrochloride manufacturer or Acoramidis Hydrochloride supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Acoramidis Hydrochloride manufacturer or Acoramidis Hydrochloride supplier.
PharmaCompass also assists you with knowing the Acoramidis Hydrochloride API Price utilized in the formulation of products. Acoramidis Hydrochloride API Price is not always fixed or binding as the Acoramidis Hydrochloride Price is obtained through a variety of data sources. The Acoramidis Hydrochloride Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Acoramidis Hydrochloride manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Acoramidis Hydrochloride, including repackagers and relabelers. The FDA regulates Acoramidis Hydrochloride manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Acoramidis Hydrochloride API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Acoramidis Hydrochloride manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Acoramidis Hydrochloride supplier is an individual or a company that provides Acoramidis Hydrochloride active pharmaceutical ingredient (API) or Acoramidis Hydrochloride finished formulations upon request. The Acoramidis Hydrochloride suppliers may include Acoramidis Hydrochloride API manufacturers, exporters, distributors and traders.
click here to find a list of Acoramidis Hydrochloride suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Acoramidis Hydrochloride as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Acoramidis Hydrochloride API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Acoramidis Hydrochloride as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Acoramidis Hydrochloride and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Acoramidis Hydrochloride NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Acoramidis Hydrochloride suppliers with NDC on PharmaCompass.
Acoramidis Hydrochloride Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Acoramidis Hydrochloride GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Acoramidis Hydrochloride GMP manufacturer or Acoramidis Hydrochloride GMP API supplier for your needs.
A Acoramidis Hydrochloride CoA (Certificate of Analysis) is a formal document that attests to Acoramidis Hydrochloride's compliance with Acoramidis Hydrochloride specifications and serves as a tool for batch-level quality control.
Acoramidis Hydrochloride CoA mostly includes findings from lab analyses of a specific batch. For each Acoramidis Hydrochloride CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Acoramidis Hydrochloride may be tested according to a variety of international standards, such as European Pharmacopoeia (Acoramidis Hydrochloride EP), Acoramidis Hydrochloride JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Acoramidis Hydrochloride USP).